

## Medicines Formulary Assessments

**Lenzetto® (estradiol 1.53mg) transdermal spray** for hormone replacement therapy in post-menopausal women—**Green**, restricted to use only when alternative transdermal products are not tolerated/contraindicated.

**Aciclovir 3% eye ointment**—**Green**, Restricted for use in herpes simplex keratitis where preservatives are not tolerated and/or in paediatrics, pregnancy or breastfeeding patients who require treatment.

**Captopril oral solution alignment with BNF advice (specialist supervised medicine)**—**SpIS** - for hypertension and heart failure in paediatrics (previously Red on Beds/Luton & Green on Milton Keynes formulary).

**Hydrocortisone kits for adrenal crisis**—**SpA**. New monograph highlighting the routes of supply of kit contents. Please note, Hydrocortisone sodium succinate 100mg powder and solvent for solution for injection vials is the preferred cost-effective choice. IM needles and 2mL syringes are not in the Drug Tariff and therefore not prescribable on FP10. These should preferably be supplied by the Specialist at routine review. Where that is not practical, surgeries could supply from practice stock or direct patients to purchase their own consumables through reputable supplier.

**Hypromellose eye drops for dry eye (Green)**— Updated preferred brands are Aapromel® or Aaculose®. Please note these contain a preservative. Consider self-care for mild dry eye. For patients unable to tolerate preservatives, carmellose (Vizcellose® or Eyeaze® brands) can be prescribed.

Lithium Formulary products have also been updated (**SCG**) —Priadel® remains the preferred brand, with continuation only of other brands (Camcolit® and Liskonium®).

Please consider referral to specialist for review of patients taking immediate release lithium. This formulation carries an increased risk of unwanted side effects and is also high cost.

## **Diclofenac systemic formulations—A reminder of [cardiovascular safety risks](#).**

Diclofenac increases the risk of heart attack and stroke and is under review within the ICS. Prescribing support messages are in development to support review. All decisions to initiate or continue use of diclofenac should be clearly documented and communicated across healthcare interface.

Naproxen and ibuprofen are the preferred Formulary NSAIDs choices for analgesia and should be recommended wherever possible above diclofenac.

## **Blood glucose testing meters—NHSE commissioning recommendations**

BLMK ICB are aware of the new guidance regarding blood glucose meters and are working with partners to review the and consider recommendations for local implementation. Further information will be available in due course.

**Milton Keynes Shared Care Guidance** is moving—Documents will now be hosted on the newly updated [BLMK ICB Shared care Guidance page](#) alongside all other area SCGs.